194 related articles for article (PubMed ID: 34009981)
1. Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins.
Chi YH; Yeh TK; Ke YY; Lin WH; Tsai CH; Wang WP; Chen YT; Su YC; Wang PC; Chen YF; Wu ZW; Yeh JY; Hung MC; Wu MH; Wang JY; Chen CP; Song JS; Shih C; Chen CT; Chang CP
J Med Chem; 2021 Jun; 64(11):7312-7330. PubMed ID: 34009981
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors.
Xu Y; Hao SY; Zhang XJ; Li WB; Qiao XP; Wang ZX; Chen SW
Bioorg Med Chem Lett; 2020 Feb; 30(3):126885. PubMed ID: 31862411
[TBL] [Abstract][Full Text] [Related]
3. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
4. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
5. TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Miura A; Sootome H; Fujita N; Suzuki T; Fukushima H; Mizuarai S; Masuko N; Ito K; Hashimoto A; Uto Y; Sugimoto T; Takahashi H; Mitsuya M; Hirai H
Invest New Drugs; 2021 Jun; 39(3):724-735. PubMed ID: 33409897
[TBL] [Abstract][Full Text] [Related]
6. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
7. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
Qi B; Xu X; Yang Y; He H; Yue X
Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.
Long L; Luo Y; Hou ZJ; Ma HJ; Long ZJ; Tu ZC; Huang LJ; Liu Q; Lu G
Eur J Med Chem; 2018 Feb; 145():805-812. PubMed ID: 29358147
[TBL] [Abstract][Full Text] [Related]
12. Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
Song D; Park Y; Yoon J; Aman W; Hah JM; Ryu JS
Bioorg Med Chem; 2014 Sep; 22(17):4855-66. PubMed ID: 25042560
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
14. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
15. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Dos Santos EO; Carneiro-Lobo TC; Aoki MN; Levantini E; Bassères DS
Mol Cancer; 2016 Feb; 15():12. PubMed ID: 26842935
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
19. Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights.
Al-Sanea MM; Elkamhawy A; Paik S; Lee K; El Kerdawy AM; Syed Nasir Abbas B; Joo Roh E; Eldehna WM; Elshemy HAH; Bakr RB; Ali Farahat I; Alzarea AI; Alzarea SI; Alharbi KS; Abdelgawad MA
Bioorg Med Chem; 2020 Jul; 28(13):115525. PubMed ID: 32371117
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
